NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
Revolution Medicines, Inc.
Ludwig Institute for Cancer Research
Dynavax Technologies Corporation
Stanford University
Icahn School of Medicine at Mount Sinai
University of Utah
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)